IPW
NBIX icon

Impact Partnership Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Impact Partnership Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Buy
+1,266
New +$188K 0.02% 409
2024
Q3 		– Sell
-2,061
Closed -$284K – 271
2024
Q2 		$284K Buy
+2,061
New +$283K 0.07% 169
2023
Q3 		– Sell
-20
Closed -$1.89K – 1139
2023
Q2 		$1.89K Buy
+20
New +$1.95K ﹤0.01% 691

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Impact Partnership Wealth's NBIX Position: Q2 2026 in Review

Impact Partnership Wealth opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,266 shares worth $213K. The stake represents 0.02% of the portfolio and ranks #409 among its holdings. This is a return to the name: Impact Partnership Wealth previously reported a position in NBIX as recently as Q2 2024.

Impact Partnership Wealth first reported a position in NBIX in Q2 2023 and has held it in 3 quarters since. The position peaked at $284K in Q2 2024. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Impact Partnership Wealth held 1,266 shares of Neurocrine Biosciences worth $213K as of Q2 2026.
  • Neurocrine Biosciences was a new Impact Partnership Wealth position in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of Impact Partnership Wealth's portfolio in Q2 2026, its #409 holding.
  • Impact Partnership Wealth first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 3 quarters since.
  • Impact Partnership Wealth's Neurocrine Biosciences position peaked at $284K in Q2 2024.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Impact Partnership Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.